It seems that hardly a week goes by in which Emergent Biosolutions doesn't get a vaccine contract. This week it's a $404 million contract with the U.S. government to provide 14.5 million doses of
Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent's strategy to expand its product portfolio with a drug
After spending $175 million in an unsuccessful effort to push a new anthrax vaccine into the clinic, VaxGen has sold the program to Emergent BioSolutions for $2 million. VaxGen also stands to earn
VaxGen and Raven Biotechnologies are backing out of their proposed merger after "stronger than anticipated opposition" from shareholders. The companies say that while they initially thought
Annapolis, MD-based PharmAthene has agreed to fork over up to $40 million to acquire the vaccines unit of the UK's Avecia Biologics. The acquisition--which is being paid for with a mix of cash and
PharmAthene has gained some powerful support in Washington for its plans to expand a herd of genetically modified goats used in drug research by housing the animals at a USDA facility in Maryland.
> Watch out, GlaxoSmithKline. The market for HIV drugs may be expanding, but it's shifting like the San Andreas Fault at the same time, and more than a handful of companies are poised to challenge
> MiddleBrook Pharmaceuticals has raised up to $10 million in a new pact with Deerfield Management.
> Genzyme says its current bid for all the shares of Bioenvision it doesn't already own is its best and final offer.
Troubled VaxGen is at it again: the company said it will reduce its workforce from 61 to 27 employees in